Relmada Therapeutics (RLMD) Current Assets (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Current Assets for 15 consecutive years, with $235.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 750.92% year-over-year to $235.3 million; the TTM figure through Mar 2026 stood at $235.3 million (up 750.92% YoY), while the FY2025 annual figure was $94.0 million, up 105.22% from the prior year.
• Current Assets climbed to $235.3 million in Q1 2026 per RLMD's latest filing, from $94.0 million in the prior quarter.
• Across five years, Current Assets topped out at $235.3 million in Q1 2026 and bottomed at $14.9 million in Q3 2025.
• Historically, Current Assets has averaged $111.5 million across 5 years, with a median of $97.5 million in 2023.
• Annual changes were most pronounced in 2025 — Current Assets sank 73.33% — and 2026, when it soared 750.92%.
• Relmada Therapeutics' Current Assets stood at $152.9 million in 2022, then slumped by 36.21% to $97.5 million in 2023, then tumbled by 53.03% to $45.8 million in 2024, then jumped by 105.22% to $94.0 million in 2025, then surged by 150.41% to $235.3 million in 2026.
• Business Quant data shows RLMD's Current Assets at $235.3 million in Q1 2026, $94.0 million in Q4 2025, and $14.9 million in Q3 2025.